Pretreatment with L-leucyl-L-leucine methyl ester (LLME) is a prerequisite for peripheral blood mononuclear cells (PBMCs) to produce antigen-specific antibodies when sensitized with an antigen. Little information, however, is available regarding the mechanisms involved in LLME-induced augmentation of antibody production from PBMCs that are antigen sensitized. In the present study, we attempted to identify the genes involved in the suppression of antibody production from PBMCs that was not treated with LLME, but sensitized with an antigen. Using subtractive screening, we obtained 63 independent genes, including 17 EST genes, that are specific for LLME-nontreated PBMC. Among these genes, the expression of heavy chain ferritin (Hferritin), CC chemokine ligand 18 (CCL18), and matrix metalloproteinase 12 (MMP12) were augmented in LLME-nontreated PBMCs, suggesting that inflammatory factors might be involved in the suppression of antibody production in LLME-nontreated PBMCs.
Monoclonal antibodies (mAb) bind to target molecules with high specificity and affinity. Hence, they are widely used in the diagnosis of and therapies for various diseases such as cancer, rheumatoid arthritis, and allergies. But, it is important to use human mAb to avoid undesirable side effects in patients. To generate human mAb in vitro, we developed an in vitro immunization protocol using human peripheral blood mononuclear cells (PBMCs). The in vitro immunization protocol used to induce antigen-specific antibody production from PBMCs consisted of two steps, pretreatment of PBMCs with L-leucyl-L-leucine methyl ester (LLME), and sensitization of PBMCs with the antigen in the presence of muramyl dipeptide (MDP), interleukin (IL)-2, and IL-4. 1) LLME is a lysosomotropic reagent that selectively eliminates monocytes, cytotoxic T lymphocytes (CTL), natural killer (NK) cells, and CD8
þ T cells but not B cells and CD4 þ T cells from human PBMCs. [2] [3] [4] [5] Although LLME is known to show toxic effects against these cells by inducing lysis and apoptosis, little information is available regarding the causes for induction of antibody production from PBMCs immunized in vitro after LLME treatment. 6) In the present study, we attempted to identify the genes involved in the suppression of antibody production from PBMCs immunized in vitro, and to present the possible mechanisms for this suppression.
Materials and Methods
Cell preparation. PBMCs were isolated from peripheral blood of healthy volunteers by Ficoll density gradient centrifugation using a lymphocyte separation medium (LSM; Organon Teknika, Durham, NC). The PBMC were treated for 20 min with 0.25 mM LLME (Bachem, Torrance, CA) in ERDF medium (Trace Scientific, Melbourne, Australia) supplemented with 10% fetal bovine serum (FBS; Invitrogen).
In vitro immunization. LLME-treated PBMCs and nontreated PBMCs (5 Â 10 6 cells each) cultured in ERDF medium supplemented with 10% FBS were sensitized with mite extract (ME; 10 mgÁml À1 ; LSL, Tokyo) along with 10 UÁml À1 IL-2 (Genzyme, Cambridge, MA), 1 mgÁml À1 IL-4 (PeproTech, London, UK), 50 mM 2-mercaptoethanol (Life Technologies, Grand Island, NY), and 10 mgÁml À1 MDP (Bachem, Bubendorf, Switzerland). RT-PCR. Total RNA was prepared from the PBMCs using a GenElute mammalian total RNA kit (Sigma, St. Louis, MO). Total RNA (500 ng) was used as a template for cDNA synthesis reaction in a total volume of 25 ml using MMLV reverse transcriptase (Promega, Madison, WI). Subsequently, PCR was performed using 1 ml of the cDNA synthesis reaction mixture and specific primers. The PCR primers were as follows: H-ferritin-sense,
Enzyme-linked immunosorbent assay (ELISA
0 . Amplification was performed through 25-30 PCR cycles (94 C for 30 s, 60 C for 30 s, and 72 C for 1 min). Reaction products were separated by polyacrylamide gel electrophoresis on a 4% gel and stained using SYBR Gold (Molecular Probes, Eugene, OR).
Subtraction. Poly (A)
þ RNA was prepared from LLME-treated and nontreated PBMCs with a Quick Prep Micro mRNA purification kit (Amersham Biosciences, Piscataway, NJ). cDNA libraries were constructed with a SMART cDNA synthesis kit (Clontech, Palo Alto, CA) according to the manufacturer's protocol, and tester and driver cDNA were synthesized using specific primers included in the PCR-Select cDNA subtraction kit (Clontech). We then subtracted driver cDNA from tester cDNA and specifically amplified the subtracted cDNA fragments with the primers used for preparation of the tester and driver cDNA. The detailed schematic protocols were provided in the instruction manual supplied with the PCR-Select cDNA subtraction kit. The amplified fragments were purified and ligated to pGEM-T Easy vector (Promega). The sequence of fragments was determined using a DNA sequencer (3100 Avant Genetic Analyzer; Applied Biosystems, Foster City, CA).
Results and Discussion

LLME treatment induces antibody production in PBMCs sensitized with antigen
Previously we reported that LLME-treated (LLME(þ)) PBMCs, but not nontreated (LLME(À)) PBMCs, induce antibody production when sensitized with an antigen (Fig. 1) . In this study, we attempted to identify the suppressive factors involved in the suppression of antibody production in LLME(À)-PBMCs sensitized with an antigen. LLME(þ)-and LLME(À)-PBMCs were collected at days 0, 1, and 3 after in vitro immunization and subjected to subtractive screening. The cDNA libraries prepared from LLME(þ)-and LLME(À)-PBMCs were used as the driver cDNA and tester cDNA respectively, and independent cDNA clones were cloned from these. Clones obtained by subtracting a cDNA library prepared from LLME(þ)-PBMCs from one from LLME(À)-PBMCs should be by derived from the cells removed by the LLME treatment. As a result of sequence determination and homology search analysis against Genbank using the BLAST program, we identified 49 cDNA clones and classified them to 36 independent cDNA clones, including 13 EST clones (Table 1) . These clones were obtained by subtracting that prepared from LLME(þ)-PBMCs from the cDNA prepared from LLME(À)-PBMCs; this suggests that these genes are involved in the suppression of antibody production from LLME(À)-PBMCs. Next, the cDNAs prepared from LLME(À)-PBMC immunized in vitro and subsequently cultured for different periods were used for subtractive screening to identify the genes involved in the maintenance of suppressed antibody production in the LLME(À)-PBMCs sensitized with an antigen. We identified 11 independent cDNA clones, including 3 EST clones (Table 1) .
Inflammation factors were involved in the suppression of antibody production in nontreated PBMCs
We selected five genes, viz., MHC class II DR, H2K binding factor 2 (KBF2), chemokine ligand 18 (CCL18), matrix metalloproteinase 12 (MMP12), and ferritin heavy chain (H-ferritin), cloned by the subtractive screening, and assessed their expression levels in the LLME(À)-PBMCs. MHC class II DR and KBF2 are known to be involved in antigen recognition and presentation at the start of an immune reaction. MHC class II DR is a component of HLA-DR on antigen presenting cells (APC), and it plays a key role in antigen presentation to T cells. 7) Although KBF2 is known to bind to the H2K molecule, its function is not completely understood. 8) As shown in Fig. 2 , no significant changes in the expression levels of these genes in LLME(À)-or LLME(þ)-PBMCs during the culture period were detected. This indicates that these genes are not involved in the downregulation of antibody production observed in LLME(À)-PBMCs.
Next we focused on CCL18, MMP12, and H-ferritin, which are known to be involved in inflammation. CCL18 is a member protein of the chemokine superfamily that plays an important role in inflammatory responses. 9) MMP12 acts on proinflammatory factors, such as cytokines, chemokines, and other proteins, to regulate varied aspects of inflammation and immunity. [10] [11] [12] Recently, it has been reported that MMP12 regulates an inflammatory response by controlling the activity and mobilization of chemokines such as CCL18. 13) Further, H-ferritin is known to be augmented by the inflammatory environment, and it elicits a suppressive function of dendritic cells (DC), resulting in attenuation of immune responses. [14] [15] [16] As Fig. 2 , shows the expressions of these genes were significantly augmented in LLME(À)-PBMCs, indicating that the inflammatory responses were strongly elicited in LLME(À)-PBMCs. Further, this suggests that an inflammatory reaction might lead to suppression of antibody production after in vitro immunization, probably through induction of the suppressive function of DC, although the exact roles of these proteins in antibody production must be investigated in future study.
In previous study, we found that IL-10, which is produced in the supernatant of LLME(À)-PBMCs, suppresses antibody production after in vitro immunization the functional alteration of DC (which occurs during preparation). Based on this finding along with the fact that IL-10 induces secretion of CCL18 from DC, IL-10 is believed to elicit suppression of antibody production after in vitro immunization by inducing functional alteration of DC mediated by inflammatory factors. In addition, it has been reported that inflammatory factors are secreted by monocytes, macrophages, and several types of dendritic cells, suggesting that these cells might be involved in the suppression of antibody production from LLME(À)-PBMCs immunized in vitro. 17, 18) Continued. ing. LLME-treated and nontreated PBMC were sensitized with an antigen, as previously described. After 1, 3, and 5 d of culture, total RNA was isolated from the PBMCs and subjected to RT-PCR analyses to assess the gene expression profiles of H-ferritin, CCL18, MMP12, MHC class II DR, KBF2, and -actin. PCR conditions and primers are described in ''Materials and Methods. '' In conclusion, we suggest that various inflammatory factors such as H-ferritin, CCL18, and MMP12 produced by cells in LLME(À)-PBMCs might suppress antibody production from PBMC immunized in vitro by inducing the functional alteration of DC.
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